What is Artios Pharma?
Artios Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel anti-cancer therapies by targeting DNA damage response (DDR) pathways. The company's pipeline includes candidates such as the ATR inhibitor alnodesertib and the DNA Polymerase theta (Pol) inhibitor ART6043, alongside pre-clinical programs like DDRi-ADCs. These therapies are engineered with distinct pharmaceutical properties and biological strategies aimed at precisely eradicating cancer cells' survival mechanisms, addressing hard-to-treat cancers.
How much funding has Artios Pharma raised?
Artios Pharma has raised a total of $385.2M across 4 funding rounds:
Series A
$33.2M
Series B
$84M
Series C
$153M
Series D
$115M
Series A (2016): $33.2M with participation from Merck Ventures, Imperial Innovations Group plc, AbbVie Ventures, SV Life Sciences, and Arix Bioscience
Series B (2018): $84M, investors not publicly disclosed
Series C (2021): $153M supported by Deep Track Capital, TCG X, Omega Funds, Invus, Sofinnova Partners, Avidity Partners, and Piper Sandler
Series D (2025): $115M, investors not publicly disclosed
Key Investors in Artios Pharma
Merck Ventures
Merck Ventures is the corporate venture capital arm of Merck, focusing on innovative technologies with the potential to significantly impact the company's core business areas. They invest globally in transformational ideas and take an active role in their portfolio companies.
Imperial Innovations Group plc
Imperial Innovations Group plc, associated with Imperial College London, supports the commercialization of cutting-edge research and technologies developed by the university, acting as a venture capital entity for innovative science and engineering ventures.
AbbVie Ventures
AbbVie Ventures is an investment entity focused on the research and development sector, particularly within biotechnology and life sciences, aligning with AbbVie's broader pharmaceutical and healthcare objectives.
What's next for Artios Pharma?
The substantial enterprise-level funding Artios Pharma has garnered positions it for accelerated development and potential commercialization of its innovative DDR-targeting oncology pipeline. This strategic investment is expected to fuel the advancement of its clinical-stage candidates and pre-clinical programs, reinforcing its mission to create new classes of medicines that exploit DDR pathways to improve outcomes for patients with challenging cancers. The company's focus on differentiated pharmaceutical properties and novel biological approaches suggests a trajectory aimed at significant market impact within the oncology sector.
See full Artios Pharma company page
